Prelude Capital Management’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-12,484
| Closed | -$220K | – | 1197 |
|
|
2024
Q1 | $220K | Buy |
+12,484
| New | +$220K | 0.01% | 950 |
|
|
2023
Q3 | – | Sell |
-33,550
| Closed | -$26.8K | – | 1049 |
|
|
2023
Q2 | $26.8K | Sell |
33,550
-512
| -2% | -$409 | ﹤0.01% | 886 |
|
|
2023
Q1 | $40K | Buy |
34,062
+18,776
| +123% | +$22K | ﹤0.01% | 916 |
|
|
2022
Q4 | $250K | Buy |
+15,286
| New | +$250K | 0.01% | 760 |
|
|
2022
Q2 | – | Sell |
-4,886
| Closed | -$37K | – | 1628 |
|
|
2022
Q1 | $37K | Buy |
4,886
+175
| +4% | +$1.33K | ﹤0.01% | 1210 |
|
|
2021
Q4 | $42K | Buy |
+4,711
| New | +$42K | ﹤0.01% | 1413 |
|
|
2020
Q2 | – | Sell |
-476
| Closed | -$31K | – | 1412 |
|
|
2020
Q1 | $31K | Buy |
+476
| New | +$31K | ﹤0.01% | 568 |
|